首页> 外国专利> KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES

KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES

机译:杀伤细胞类莱克汀样受体家族G成员1(KLRG1)消耗性抗体

摘要

The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.
机译:受体杀伤细胞凝集素样受体G1(KLRG1)在T和NK细胞上表达,与上皮和间充质细胞上的配体结合。 KLRG1的配体已被描述为E-钙粘蛋白,N-钙粘蛋白和R-钙粘蛋白。本公开涉及发现并表征结合KLRG1的细胞外结构域(ECD)但不干扰其与配体E-钙粘着蛋白,N-钙粘着蛋白和R-钙粘着蛋白的相互作用的抗体并从中得到结果。所描述的抗体是通过小鼠杂交瘤技术衍生的,可以通过将其互补决定区(CDR)移植到人框架中来实现人源化。所述抗体可以用作有效的治疗剂。在本公开中提供了各种抗体或这种抗体的抗原结合片段,以及各种治疗和/或诊断方法,以及其他特征。

著录项

  • 公开/公告号US2020325233A1

    专利类型

  • 公开/公告日2020-10-15

    原文格式PDF

  • 申请/专利权人 ABCURO INC.;

    申请/专利号US202016844747

  • 申请日2020-04-09

  • 分类号C07K16/28;

  • 国家 US

  • 入库时间 2022-08-21 11:26:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号